GLI2 and non-small cell lung carcinoma: However, GANT61, a direct inhibitor of GLI2, was demonstrated to have appropriate anti-NSCLC efficacy in vitro and in vivo31, indicating that the GLI2 inhibition seemed to be related to the anti-LUAD effect of Shh inhibitors.